irix-8k_20191107.DOCX.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8‑K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

November 7, 2019

 

(Date of Report (date of earliest event reported)

IRIDEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

0-27598

77-0210467

(State or other jurisdiction of
incorporation or organization)

(Commission File Number)

(I.R.S. Employer
Identification Number)

1212 Terra Bella Avenue
Mountain View, California 94043

(Address of principal executive offices, including zip code)

 

(650) 940-4700

 

 

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Securities registered pursuant to Section 12(b) of the Act:

Title of Class

 

Trading

Symbol

 

Name of Exchange on Which Registered

Common Stock, par value $0.01 per share

 

IRIX

 

Nasdaq Global Market

 

 


 

 

 

 

 

Item 2.02.Results of Operations and Financial Condition.

 

 On November 7, 2019, IRIDEX Corporation issued a press release discussing its financial results for its third fiscal quarter of 2019, which ended on September 28, 2019.  The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

 

This information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

Item 9.01.Financial Statements and Exhibits.

 

 

 

(d)

Exhibits

 

 

 

 

Exhibit No.

 

Description

 

 

99.1

 

Press Release dated November 7, 2019.

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

IRIDEX CORPORATION

 

 

By:

 

/s/ David I. Bruce

 

 

David I. Bruce

President and Chief Executive Officer

Date: November 7, 2019

 

 

-2-

irix-ex991_6.htm

 

 

Exhibit 99.1

 

MOUNTAIN VIEW, Calif., November 7, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 28, 2019.

 

Third Quarter Highlights

 

Total revenue of $10.7 million

 

Cyclo G6® product family revenue of $3.0 million, a 3.6% year-over-year increase

 

o

Shipped 11,600 Cyclo G6 probes, a 12% year-over-year increase

 

o

Shipped 82 Cyclo G6 Glaucoma Laser Systems, compared to 117 the prior year

 

Achieved $1.5 million reduction in operating expenses versus the third quarter of 2018

 

Ergonomically improved MicroPulse P3® glaucoma probe ready for commercial roll-out, following favorable initial clinical experience

 

Additional clinical evidence of MicroPulse® transscleral laser therapy’s strong efficacy, durability and safety profile, including the first peer-reviewed publication on the use of the technology on patients with good vision and mild to severe glaucoma, concluding that MicroPulse transscleral therapy is an effective alternative and could be offered to patients prior to incisional glaucoma procedures (published in the Journal of Glaucoma)

 

“Following my first full quarter as CEO, I was pleased with both the stability of our retina business and growth in our glaucoma business, particularly as we execute the transition from a prior emphasis on customer site placements to a new emphasis on physician adoption and procedure growth,” said David I. Bruce, President and CEO. “We believe the fourth quarter rollout of our enhanced glaucoma probe is a key step helping drive this transition. In addition, our focus on cost efficiency resulted in a 20% reduction in operating expenses during the quarter versus last year.”

 

Third Quarter 2019 Financial Results

Total revenue for the three months ended September 28, 2019 of $10.7 million, represented a decrease of 5.8% from $11.3 million during the same period of 2018.

 

Revenue from IRIDEX’s Cyclo G6 glaucoma products was $3.0 million, representing growth of 3.6% over the same period in the prior year. The ongoing strategic shift from the Company’s previous focus on site placements resulted in a 30% decline in Cyclo G6 system shipments; however, Cyclo G6 system revenues declined only 12%, as the average selling price improved compared to the prior year period during which discounted packages were promoted. Cyclo G6 probe shipments grew 12% as the Company transitioned sales drivers to focus on reorder growth and adding ongoing customers, which more than offset the effect of discontinuing discount packages. However, the combination of reduced volume packages, inventory usage and launch of the updated MicroPulse P3 glaucoma probe is temporarily depressing overall probe growth. Accordingly, the Company adjusted its full year probe shipment guidance to 53,000 to 56,000, which at the midpoint reflects year-over-year growth of 20%.

 

Revenue from retina products in the quarter was $5.8 million, versus $5.2 million in the prior quarter and $6.7 million in the third quarter of 2018. During the third quarter of 2018, the Company booked approximately $1.3 million in orders from its Chinese distributor ahead of the pending U.S. tariff increases, compared to approximately $0.4 million in the third quarter of 2019. In addition, last year’s

 


 

third quarter retina revenue included significant backorder volume following clearance of the voluntary recall of its LIO products.

 

Gross profit for the third quarter of 2019 was $4.3 million, a 40.2% gross margin, compared to $4.6 million, a 40.4% gross margin in the same period of the prior year.

 

Operating expenses for the third quarter of 2019 decreased to $6.1 million compared to $7.6 million in the same period of the prior year. The decrease reflects the Company’s focus on operating costs and cash usage, including reductions in headcount and related costs, lower administrative expenses, and efficiencies gained in adjustments to the Company’s sales, marketing and engineering programs.  

 

The loss from operations for the third quarter of 2019 decreased to $1.9 million, compared to a loss from operations of $3.1 million for the same period of the prior year.

 

Net cash used in the quarter was $2.7 million, resulting in cash and cash equivalents of $12.9 million and no debt as of September 28, 2019.

 

Guidance for Full Year 2019

IRIDEX reiterated its revenue guidance for the full year 2019 of $41 million to $44 million and Cyclo G6 system shipments of 375 to 425. The Company revised its guidance for shipments of Cyclo G6 probes from 58,000 to 63,000 down to 53,000 to 56,000, which at the midpoint reflects year-over-year growth of 20%. The reduction in guidance reflects the impact of the Company’s sales transition towards reorder growth and acquiring new ongoing customers, along with customer inventory adjustments resulting from the roll out of improved glaucoma probes in the United States.

 

Webcast and Conference Call Information

IRIDEX’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET.  Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 4584326. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.  

 

About IRIDEX

IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at www.iridex.com.

 

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the future demand, utilization and order levels for the Company's

 

 


 

products, and the Company’s guidance for fiscal year 2019 and future financial results. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2018, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

 

Investor Relations Contact

Leigh Salvo

(415) 937-5404

investors@iridex.com

 


 


 

 

 

IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(unaudited)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 28,

 

 

September 29,

 

 

September 28,

 

 

September 29,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total revenues

 

$

10,664

 

 

$

11,320

 

 

$

31,685

 

 

$

31,133

 

Cost of revenues

 

 

6,381

 

 

 

6,744

 

 

 

18,596

 

 

 

18,367

 

Gross profit

 

 

4,283

 

 

 

4,576

 

 

 

13,089

 

 

 

12,766

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

1,007

 

 

 

1,149

 

 

 

2,894

 

 

 

3,154

 

Sales and marketing

 

 

3,508

 

 

 

4,144

 

 

 

11,061

 

 

 

12,362

 

General and administrative

 

 

1,621

 

 

 

2,343

 

 

 

6,491

 

 

 

7,209

 

Total operating expenses

 

 

6,136

 

 

 

7,636

 

 

 

20,446

 

 

 

22,725

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(1,853

)

 

 

(3,060

)

 

 

(7,357

)

 

 

(9,959

)

Other income (expense), net

 

 

  75

 

 

 

(8

)

 

 

127

 

 

 

16

 

Loss from operations before provision for income taxes

 

 

(1,778

)

 

 

(3,068

)

 

 

(7,230

)

 

 

(9,943

)

Provision for income taxes

 

 

7

 

 

 

6

 

 

 

22

 

 

 

14

 

Net loss

 

$

(1,785

)

 

$

(3,074

)

 

$

(7,252

)

 

$

(9,957

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    Basic

 

$

(0.13

)

 

$

(0.26

)

 

$

(0.53

)

 

$

(0.85

)

    Diluted

 

$

(0.13

)

 

$

(0.26

)

 

$

(0.53

)

 

$

(0.85

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used in computing net loss per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    Basic

 

 

13,768

 

 

 

11,925

 

 

 

13,682

 

 

 

11,732

 

    Diluted

 

 

13,768

 

 

 

11,925

 

 

 

13,682

 

 

 

11,732

 

 

 

 


 


 

IRIDEX Corporation

Condensed Consolidated Balance Sheets

(In thousands and unaudited)

 

 

 

September 28,

 

 

December 29

,

 

 

2019

 

 

2018

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

12,948

 

 

$

21,194

 

Accounts receivable, net

 

 

8,784

 

 

 

9,083

 

Inventories

 

 

8,896

 

 

 

8,794

 

Prepaid expenses and other current assets

 

 

590

 

 

 

547

 

Total current assets

 

 

31,218

 

 

 

39,618

 

Property and equipment, net

 

 

876

 

 

 

1,220

 

Intangible assets, net

 

 

88

 

 

 

100

 

Goodwill

 

 

533

 

 

 

533

 

Operating lease right-of-use assets, net

 

 

3,056

 

 

 

-

 

Other long-term assets

 

 

187

 

 

 

201

 

Total assets

 

$

35,958

 

 

$

41,672

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,429

 

 

$

2,516

 

Accrued compensation

 

 

1,944

 

 

 

2,962

 

Accrued expenses

 

 

1,634

 

 

 

2,763

 

Accrued warranty

 

 

376

 

 

 

622

 

Deferred revenue

 

 

1,528

 

 

 

1,639

 

Operating lease liabilities

 

 

1,388

 

 

 

-

 

Total current liabilities

 

 

9,299

 

 

 

10,502

 

 

 

 

 

 

 

 

 

 

Long-term liabilities:

 

 

 

 

 

 

 

 

Accrued warranty

 

 

137

 

 

 

238

 

Deferred revenue

 

 

366

 

 

 

586

 

Operating lease liabilities

 

 

2,151

 

 

 

-

 

Other long-term liabilities

 

 

17

 

 

 

385

 

Total liabilities

 

 

11,970

 

 

 

11,711

 

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

147

 

 

 

145

 

Additional paid-in capital

 

 

72,793

 

 

 

71,548

 

Accumulated other comprehensive income

 

 

102

 

 

 

70

 

Accumulated deficit

 

 

(49,054

)

 

 

(41,802

)

Total stockholders' equity

 

 

23,988

 

 

 

29,961

 

 

Total liabilities and stockholders' equity

 

$

35,958

 

 

$

41,672